Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Resected Pancreatic Cancer Using Organoid
Status
Conditions
Treatments
Details and patient eligibility
About
The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as adjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within pancreatic cancer patients eligible for surgery, the investigators aim to strategize appropriate adjuvant chemotherapy after surgery, thus developing a platform to predict the outcomes of each patient.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- 18 years old or older
- Newly discovered pancreatic cancer and not a relapse
- Diagnosed with pancreatic cancer via EUS-FNA, EUS-FNB before surgery
- Patients who can undergo surgery for pancreatic cancer
- Diagnosed with pancreatic cancer from the final tissue pathology diagnosis after surgery
- who is in need of adjuvant chemotherapy after surgery
- Able to make decisions for oneself for participation
- Has obtained voluntary consent in written form (if 70 years of age or older, receive consent from the guardian as well)
Exclusion criteria
- None
Trial design
300 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Joo Kyung Park, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal